Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Nissan Chemical, The Current Fiscal Year Ordinary Profit Revised Upward by 5%, Highest in Two Terms
4021 Nissan Chemical Corporation 【J-GAAP】
Earnings ReportNissan Chemical Corporation <4021> [TSE Prime] announced its financial results after the market closed on February 7th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) increased 23.6% from the same period last year, reaching 43.3 billion yen.
In addition, the full-year consolidated ordinary profit has been revised upward 5.1%, from the previous forecast of 53.2 billion yen to 55.9 billion yen (compared to 51.6 billion yen in the previous period), increasing the growth rate from 3.0% to 8.3%, reaches new record high for the first time in two terms.
Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the October to March period (2H) is expected to increase 10.7%, from the previous forecast of 25.2 billion yen to 27.9 billion yen (compared to 25.4 billion yen in the same period of the previous year), turning to a 9.9% increase in the consolidated ordinary profit outlook.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit increased 73.8% from the same period last year, reaching 15.3 billion yen. The operating profit margin rose from 18.8% in the same period last year to 22.5%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Dec, 2022 | 159,234 | 38,811 | 41,341 | 30,760 | 218.0 | 74.1 | Feb 10, 2023 | J-GAAP |
Apr - Dec, 2023 | 155,334 | 33,436 | 35,049 | 25,972 | 186.0 | 67.9 | Feb 9, 2024 | J-GAAP |
Apr - Dec, 2024 | 174,832 | 41,080 | 43,326 | 31,708 | 230.3 | 77.5 | Feb 7, 2025 | J-GAAP |
YoY | +12.6% | +22.9% | +23.6% | +22.1% | +23.8% |
Guidance Update
Second Half Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2024 Prev | 126,815 | 24,656 | 25,255 | 18,878 | 138.2 | 94 | Nov 11, 2024 | J-GAAP |
Oct - Mar, 2024 New | 129,415 | 26,656 | 27,955 | 20,378 | 149.2 | 94 | Feb 7, 2025 | J-GAAP |
Revision Rate | +2.1% | +8.1% | +10.7% | +7.9% | +7.9% |
Full Year Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2025 Prev | 245,000 | 53,000 | 53,200 | 39,400 | 288.4 | 164 | Nov 11, 2024 | J-GAAP |
Mar, 2025 New | 247,600 | 55,000 | 55,900 | 40,900 | 299.4 | 164 | Feb 7, 2025 | J-GAAP |
Revision Rate | +1.1% | +3.8% | +5.1% | +3.8% | +3.8% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2023 | 121,030 | 24,107 | 25,432 | 18,536 | 133.0 | 94 | May 13, 2024 | J-GAAP |
Oct - Mar, 2024 Guidance | 129,415 | 26,656 | 27,955 | 20,378 | 149.2 | 94 | Feb 7, 2025 | J-GAAP |
YoY | +6.9% | +10.6% | +9.9% | +9.9% | +12.2% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 228,065 | 52,283 | 55,793 | 41,087 | 291.4 | 164 | May 15, 2023 | J-GAAP |
Mar, 2024 | 226,705 | 48,201 | 51,629 | 38,033 | 272.8 | 164 | May 13, 2024 | J-GAAP |
Mar, 2025 Guidance | 247,600 | 55,000 | 55,900 | 40,900 | 299.4 | 164 | Feb 7, 2025 | J-GAAP |
YoY | +9.2% | +14.1% | +8.3% | +7.5% | +9.7% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 49,659 | 9,342 | 8,852 | 6,475 | 46.4 | 18.8 | Feb 9, 2024 | J-GAAP |
Jan - Mar, 2024 | 71,371 | 14,765 | 16,580 | 12,061 | 86.5 | 20.7 | May 13, 2024 | J-GAAP |
Apr - Jun, 2024 | 58,688 | 14,426 | 16,029 | 11,590 | 83.8 | 24.6 | Aug 9, 2024 | J-GAAP |
Jul - Sep, 2024 | 59,497 | 13,918 | 11,916 | 8,932 | 64.8 | 23.4 | Nov 11, 2024 | J-GAAP |
Oct - Dec, 2024 | 56,647 | 12,736 | 15,381 | 11,186 | 81.2 | 22.5 | Feb 7, 2025 | J-GAAP |
YoY | +14.1% | +36.3% | +73.8% | +72.8% | +75.2% |
Related Articles
TENMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 33%, Oct-Dec Ordinary Profit Decreases by 28%
SUMCO, 48% Decrease in Ordinary Profit for the Last Fiscal Year, Current period performance is undisclosed.
PORTERS, 10% Decrease in Ordinary Profit for The Current Fiscal Year
RENOVA, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Turns to Loss
TS TECH, Apr-Dec (Cumulative 3Q) Net Income Decreases by 13%, Oct-Dec Net Income Decreases by 44%
Procrea Holdings, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 96%, Exceeds Full-Year Plan
TORII PHARMA, 35% Decrease in Ordinary Profit for The Current Fiscal Year
KAPPA CREATE, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 22%, Oct-Dec Ordinary Profit Decreases by 6%
RENAISSANCE INC, The Current Fiscal Year Ordinary Profit Revised Upward by 20%, Dividend Revised Upward by 1 yen
Broadleaf, Last Fiscal Year's Net Income Exceeds Expectations, 2.9 times Increase in Net Income for The Current Fiscal Year, Dividend Raised by 2 yen